Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 117

Results For "TD"

1251 News Found

Lupin launches generic version of Brovana in US
News | June 04, 2021

Lupin launches generic version of Brovana in US

Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction


Govt. to procure 30 Cr COVID-19 vaccine doses from Biological-E
News | June 03, 2021

Govt. to procure 30 Cr COVID-19 vaccine doses from Biological-E

These vaccine doses will be manufactured and stockpiled by the company from August-December 2021


Panacea Biotec posts consolidated Q4FY21 loss of Rs. 54.14 crore
News | June 03, 2021

Panacea Biotec posts consolidated Q4FY21 loss of Rs. 54.14 crore

The company reported total income of Rs.634.79 crores during the 12 months period ended March 31, 2021


Sun Pharma and Ferring Pharmaceuticals to introducing CARITEC in India
News | June 03, 2021

Sun Pharma and Ferring Pharmaceuticals to introducing CARITEC in India

Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC


Lupin to foray into the digital healthcare space
Digitisation | June 03, 2021

Lupin to foray into the digital healthcare space

The company recently incorporated a new entity in the name of Lupin Digital Health Limited


Progress on new ventures key for Aurobindo Pharma: ICICI Securities
News | June 02, 2021

Progress on new ventures key for Aurobindo Pharma: ICICI Securities

Aurobindo has one of the most enduring generics ecosystems among peers


Lasa Supergenerics FY21 profit up 521%
News | June 02, 2021

Lasa Supergenerics FY21 profit up 521%

Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%


Marksans Pharma Q4 FY21 profit up 86%
News | June 01, 2021

Marksans Pharma Q4 FY21 profit up 86%

The company's operating revenue for Q4 FY21 was Rs. 330.2 crore


Margins impacted by high expenses for Pfizer: ICICI Securities
News | May 31, 2021

Margins impacted by high expenses for Pfizer: ICICI Securities

Adjusted PAT declined 18.8% YoY


Cadila Healthcare’s margin supported by lower R&D : ICICI Securities
Drug Approval | May 31, 2021

Cadila Healthcare’s margin supported by lower R&D : ICICI Securities

India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact